Skip to main content


1. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D.: Survey of chronic pain in Europe:
Prevalence, impact on daily life, and treatment. Eur J Pain 2006, 10:287-333.
3. McQuaid KR, Laine L.: Systematic review and meta-analysis of adverse events of low-dose aspirin and
clopidogrel in randomized controlled trials. Am J Med. 2006;119: 624-38.
4. Boers M, Tangelder MJ, van Ingen H, Fort JG, Goldstein JL.: The rate of nsaid-induced endoscopic
ulcers increases linearly, but not exponentially with age: a pooled analysis of 12 randomized trials. Ann
Rheum Dis. 2006 Aug 3; (Epub ahead of print)
5. Hernandez-Diaz S, Garcia Rodriguez LA.: Cardioprotective aspirin users and their excess risk of upper
gastrointestinal complications. BMC Med. 2006; 4:22.
6. Silvani MC, Motola D, Poluzzi E, Bottoni A, De Ponti F, Vaccheri A, Montanaro N.: Gastro-intestinal
problems and concomitant medication in NSAID users: additional findings from a questionnaire-based
survey in Italy. Eur J Clin Pharmacol. 2006; 62: 235-41.
7. Steinman MA, McQuaid KR, Covinsky KE.: Age and rising rates of cyclooxygenase-2 inhibitor use.
Results from a national survey. J Gen Intern Med. 2006; 21: 245-50.
8. Garcia EB, Michaud K, Wolfe F.: Gastrointestinal prophylactic therapy among patients with arthritis
treated by rheumatology specialists. J Rheumatol. 2006; 33: 779-84.
9. Goldstein JL, Aisenberg J, Lanza F, Schwartz H, Sands GH, Berger MF, Pan S.: A multicenter, randomized,
double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of
endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to
75 years. Clin Ther. 2006; 28: 340-51.
10. Wilder-Smith CH, Jonzon B, Fornstedt-Wallin B, Hedman A, Karlsson P.: Dose-effect comparisons of
the CINOD AZD3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects.
Scand J Gastroenterol. 2006; 41: 264-73.
11. Chen JT, Pucino F, Resman-Targoff BH.: Celecoxib versus a non-selective NSAID plus proton-pump
inhibitor: what are the considerations?. J Pain Palliat Care Pharmacother. 2006; 20: 11-32.
12. Lanas A.: Prevention and treatment of NSAID-induced gastroduodenal injury. Curr Treat Options
Gastroenterol. 2006; 9: 147-56.
13. Wex T, Ye S, Treiber G, Vieth M, Roessner A, Malfertheiner P.: Helicobacter pylori infection, but not
562 Gastro Update 2007
low-dose aspirin, results in a local reduction of the secretory leukocyte protease inhibitor in gastro
duodenal mucosa. Helicobacter. 2006; 11: 31-8.
14. Ji KY, Hu FL.: Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory
drugs in upper gastrointestinal diseases. World J Gastroenterol. 2006; 12: 3789-92.
15. Maino M, Mantovani N, Merli R, Cavestro GM, Leandro G, Cavallaro LG, Corrente V, Iori V, Pilotto
A, Franze A, Di Mario F.: Effects of chronic therapy with non-steroidal antiinflammatory drugs on gastric
permeability of sucrose: a study on 71 patients with rheumatoid arthritis. World J Gastroenterol. 2006;
12: 5017-20.
16. Petruzzelli M, Moschetta A, Renooij W, de Smet MB, Palasciano G, Portincasa P, van Erpecum KJ.:
Indomethacin enhances bile salt detergent activity: relevance for NSAIDs-induced gastrointestinal
mucosal injury. Dig Dis Sci. 2006; 51: 766-74.
17. Yeomans ND, Svedberg LE, Naesdal J.: Is ranitidine therapy sufficient for healing peptic ulcers associated
with non-steroidal anti-inflammatory drug use? Int J Clin Pract. 2006; 60: 1401-7.
18. Becker JC, Grosser N, Waltke C, Schulz S, Erdmann K, Domschke W, Schroder H, Pohle T.: Beyond
gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial
cells. Biochem Biophys Res Commun. 2006; 345: 1014-21.
19. Adebayo D, Bjarnason I.: Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more
important than NSAID gastropathy? Postgrad Med J. 2006; 82: 186-91.